NCT00377455 - Placebo Controlled Trial of Bosentan in Scleroderma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

March 31, 2010

Conditions

Systemic SclerodermaPulmonary Hypertension

Interventions

DRUG

Bosentan

62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks

DRUG

Placebo

62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks

Trial Locations (2)

Georgetown University Medical Center, Washington D.C.

University of Connecticut, Farmington